The Next Layer of Preventive Health Starts Here

The problem
Millions of people live with symptoms that have no clear explanation: persistent fatigue, poor sleep, weight changes, digestive problems, low energy, brain fog. They see several specialists and run test after test. Problems are recognized late, and diagnosis comes late. The cost is high for patients, for health systems and for society.

Our solution: DMA®
DMA® is a non-invasive, AI-powered metabolic screening platform. In a single short session it captures the body's bioelectrical signals and turns them into a structured metabolic profile. Each Symptom and and Disease has its metabolic fingerprint. DMA reads such fingerprint.

Why it's defensible
DMA® comes from years of work combining systems biology, mathematical modeling, optimization and AI. Our moat is the modeling engine and the data that builds up with every session, not the hardware.

Three product lines, each with its own intended use

• DMA® Screening: complementary metabolic information for healthcare settings (EU MDR Class I pathway).

• DMA® Diagnostics: a tool to support healthcare professionals in diagnosis and monitoring (higher-class regulatory pathway, in progress).

• DMA® Performance: sport, wellness and longevity, positioned under general-wellness use with no disease claims.

Business model
We use a recurring-service model, delivered mainly through a B2B2C network of clinics, wellness centers and franchise partners. Each installed point creates repeat sessions and a growing data asset.

Where we are
We are completing our EU regulatory and quality foundations (MDR, ISO 13485). We have active market development in Europe, the United States and the UAE.

Team
Math Biology is led by a founder with a prior exit in advanced modeling and AI. The team includes senior pharma R&D leadership, academic expertise in mathematical optimization, and US-based advisors.

The opportunity
We are opening a funding round to scale commercial rollout, advance the regulatory roadmap including the US pathway, and expand clinical evidence. We are looking for investors who share our view that preventive, data-driven health should be fast, non-invasive and accessible.

Information on the round is available to qualified investors on request.